.svg){kind=small}
Phase I & II clinical trial expertise
Our substantial experience of developing and conducting adaptive protocols for Phase I and II trials enables us to maximise the return on our sponsors’ studies whilst guaranteeing the safety of our participants.
Benefits of using our Phase I & II clinical trials
Adding value by gathering more and highly relevant data. We only collect and analyse essential data to meet the trial objectives within a limited budget.
We limit assessments and participant exposure to what is relevant and essential. Tailoring our adaptive limits and control mechanisms for each protocol to manage potential risks.
Umbrella protocols to maximise efficiency. We integrate ethnic comparison elements, intensive cardiac assessments, and other biomarkers into a combined umbrella protocol - avoiding potential risks in further drug development.
We maximise return on our sponsors' trials
Using adaptive design to support rational “no-go” or “where to go next” decisions, an entire early phase programme from First-In-Human to Proof of Concept can be performed in one trial protocol, in one trial centre.
Why choose Richmond Pharmacology for your Early Phase Studies
Systematic and logical protocols
We adapt the trial design whilst maintaining the validity of the data and integrity of the trial.
Rapid approval
We have an excellent track record for starting studies on time and effectively managing ethics and regulatory submissions.
Time efficient
Fast and efficient adaptive protocol development using a transparent and systematic approach.
Hear from our sponsors
.svg){kind=small}
-min.jpg)
.jpg)
Latest news
Futureproofing early phase clinical research for the next generation of investigators.
Director of Operations, Keith Berelowitz, has been appointed as the Research Ethics Committee Chair for the Health Research Authority.
Events
13th International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions
